Susan D. Richman

6.4k citations

76 papers · 3.2k indexed · 2 hit papers · h-index 21

Oncology top 1%
Pathology and Forensic Medicine top 0.5%
Cancer Research top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology top 10%

Co-authors: Philip Quirke Michel Seymour Philip Chambers Catherine Daly Faye Elliott Jennifer H. Barrett Angela Meade Tim Maughan
Topics: Colorectal Cancer Treatments and Studies (59 papers)Genetic factors in colorectal cancer (26 papers)Cancer Genomics and Diagnostics (24 papers)
Cited by: Oncology Pathology and Forensic Medicine Cancer Research
Journals: The Lancet Nature Communications Journal of Clinical Oncology
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Susan D. Richman

72 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

2014 534 citations Sabine Venderbosch, Irıs D. Nagtegaal et al. Clinical Cancer Research profile →
Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

2011 505 citations Gordon Hutchins, Katie Southward et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Susan D. Richman

Since Specialization

Citations

This map shows the geographic impact of Susan D. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan D. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan D. Richman more than expected).

Fields of papers citing papers by Susan D. Richman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan D. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan D. Richman. The network helps show where Susan D. Richman may publish in the future.

Co-authorship network of co-authors of Susan D. Richman

This figure shows the co-authorship network connecting the top 25 collaborators of Susan D. Richman. A scholar is included among the top collaborators of Susan D. Richman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan D. Richman. Susan D. Richman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multiplexed Digital PCR Reference Gene Measurement for Genomic and Cell-Free DNA Analysis 2025 ·Cells ·(unknown),(unknown),Jo Vandesompele,(unknown),Susan D. Richman,Henry M. Wood,Jim F. Huggett,Carole A. Foy,Alison S. Devonshire	0
2	Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy 2024 ·npj Precision Oncology ·Maxime W. Lafarge,Enric Domingo,Korsuk Sirinukunwattana,(unknown),Leslie Samuel,Graeme I. Murray,Susan D. Richman,Andrew Blake,David Sebag‐Montefiore,Simon Gollins,E. Klieser,Daniel Neureiter,Florian Huemer,Richard Greil,Philip D. Dunne,Philip Quirke,Lukas Weiß,Jens Rittscher,Tim Maughan,Viktor H. Koelzer	9
3	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone 2021 ·British Journal of Cancer ·Sanne ten Hoorn,Dirkje W. Sommeijer,Faye Elliott,David J. Fisher,Tim R. de Back,Anne Trinh,Lianne Koens,Tim Maughan,Jenny F. Seligmann,Michel Seymour,Philip Quirke,Richard Adams,Susan D. Richman,Cornelis J.A. Punt,Louis Vermeulen	11
4	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA 2021 ·Epigenomes ·Celina Whalley,Karl Payne,Enric Domingo,Andrew Blake,Susan D. Richman,Jill Brooks,Nikolaos Batis,Rachel Spruce,Hisham Mehanna,Paul Nankivell,Andrew D. Beggs	9
5	Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA 2021 ·Scientific Reports ·Thomas L. Dunwell,(unknown),(unknown),(unknown),Philipp Becker,Sarah Scaife,Susan D. Richman,Henry M. Wood,(unknown),(unknown),Xiangsheng Yang,Hui Xiao,Sissel Gyrid Freim Wahl,Bjørn Henning Grønberg,(unknown),Guoliang Fu	4
6	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment 2020 ·Molecular Oncology ·(unknown),Stephanie G. Craig,Victoria Bingham,(unknown),Matthew P. Humphries,(unknown),Susan D. Richman,Philip Quirke,Leticia Campo,Enric Domingo,Tim Maughan,Jacqueline A. James,Manuel Salto‐Tellez	69
7	Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel 2020 ·Annals of Oncology ·Jenny F. Seligmann,Faye Elliott,Susan D. Richman,Gemma Hemmings,Sarah Brown,Bart Jacobs,Christopher J.M. Williams,Sabine Tejpar,Jennifer H. Barrett,Philip Quirke,Michel Seymour	12
8	Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies 2018 ·The Journal of Pathology ·(unknown),Susan D. Richman,Simon Gollins,Peter Stewart,Chris Hurt,Richard Adams,Amy M.B. McCorry,(unknown),Dale Vimalachandran,Claudio Isella,Enzo Médico,Tim Maughan,Darragh G. McArt,Mark Lawler,Philip D. Dunne	40
9	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification 2017 ·Nature Communications ·Philip D. Dunne,(unknown),Paul G. O’Reilly,(unknown),Amy M.B. McCorry,Susan D. Richman,Tim Maughan,Simon S. McDade,Patrick G. Johnston,Daniel B. Longley,Elaine W. Kay,Darragh G. McArt,Mark Lawler	53
10	FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA 2017 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Susan D. Richman,Richard Adams,Ewan Brown,Lynne Brown,Rachel Butler,(unknown),David I. Fisher,Raphael Kaplan,Gary Middleton,Philip Quirke,Leslie Samuel,Jenny F. Seligmann,Seymour,(unknown),Harpreet Wasan,Richard H. Wilson,Tim Maughan	1
11	Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC) 2017 ·Annals of Oncology ·Jenny F. Seligmann,Henry M. Wood,Susan D. Richman,Faye Elliott,Morag Taylor,Emma Tinkler‐Hundal,Jennifer H. Barrett,Michel Seymour,Philip Quirke	2
12	FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS 2016 ·Annals of Oncology ·Richard Adams,Ewan Brown,Louise Brown,Rachel Butler,(unknown),David J. Fisher,Raphael Kaplan,Philip Quirke,Susan D. Richman,Leslie Samuel,Jenny F. Seligmann,Michel Seymour,Kai‐Keen Shiu,Harpreet Wasan,Richard H. Wilson,Tim Maughan	3
13	Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials 2016 ·Annals of Oncology ·Jenny F. Seligmann,David J. Fisher,Christopher G. Smith,Susan D. Richman,Faye Elliott,Sarah Brown,Richard Adams,Tim Maughan,Philip Quirke,Jeremy P. Cheadle,Michel Seymour,Gary Middleton	124
14	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival 2015 ·Clinical Cancer Research ·Christopher G. Smith,David J. Fisher,Rebecca Harris,Tim Maughan,Amanda I. Phipps,Susan D. Richman,Michel Seymour,Ian Tomlinson,Dan Rosmarin,David Kerr,Andrew T. Chan,Ulrike Peters,Polly A. Newcomb,Shelley Idziaszczyk,Hannah D. West,Angela Meade,Richard Kaplan,Jeremy P. Cheadle	16
15	Deficient mismatch repair: Read all about it (Review) 2015 ·International Journal of Oncology ·Susan D. Richman	127
16	Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studiesbreakdown → 2014 ·Clinical Cancer Research ·Sabine Venderbosch,Irıs D. Nagtegaal,Tim Maughan,Christopher G. Smith,Jeremy P. Cheadle,David J. Fisher,Richard Kaplan,Philip Quirke,Michel Seymour,Susan D. Richman,Gerrit A. Meijer,Bauke Ylstra,Daniëlle A.M. Heideman,Anton F. J. de Haan,Cornelis J.A. Punt,Miriam Koopman	534
17	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO) 2013 ·European Journal of Cancer ·Gary Middleton,Sarah Brown,Catherine Lowe,Tim Maughan,Stephen J. Gwyther,Alfred Oliver,Susan D. Richman,(unknown),Vicky Napp,Helen Marshall,Jonathan Wadsley,Nick Maisey,Ian Chau,Mark Hill,Simon Gollins,Sun Myint,Sarah Slater,John Wagstaff,John Bridgewater,Michel Seymour	19
18	Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancerbreakdown → 2011 ·Journal of Clinical Oncology ·Gordon Hutchins,Katie Southward,Kelly Handley,Laura Magill,Claire Beaumont,Jens Stahlschmidt,Susan D. Richman,Philip Chambers,Michel Seymour,David Kerr,Richard Gray,Philip Quirke	505
19	MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer 2008 ·International Journal of Cancer ·James M. Allan,(unknown),Julian Adlard,Jonathan Bury,(unknown),(unknown),Mark Katory,Philip Quirke,Susan D. Richman,Daniel Scott,Kathryn Scott,Michel Seymour,Lois B. Travis,Lisa Worrillow,D. Timothy Bishop,Angela Cox	41
20	Prediction of the response of colorectal cancer to systemic therapy 2002 ·The Lancet Oncology ·Julian Adlard,Susan D. Richman,Michel Seymour,Philip Quirke	79

About Susan D. Richman

Susan D. Richman is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 76 papers that have together received 3.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (59 papers), Genetic factors in colorectal cancer (26 papers) and Cancer Genomics and Diagnostics (24 papers). The work is most often cited by research in Oncology (2.6k citations), Pathology and Forensic Medicine (1.6k citations) and Cancer Research (711 citations). Susan D. Richman has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Philip Quirke, Michel Seymour, Philip Chambers, Catherine Daly, Faye Elliott, Jennifer H. Barrett, Angela Meade, Tim Maughan, Gordon Hutchins and David Kerr. Their work appears in journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact